The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics and outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617 (PSMA-RLT) in a real-world setting.
 
David Kersting
Research Funding - Pfizer (Inst)
 
Moon-Sung Kim
No Relationships to Disclose
 
Lukas Puellen
No Relationships to Disclose
 
Kathi Seidl-Rathkopf
Employment - Flatiron Health
Stock and Other Ownership Interests - Roche
 
Nicole Schinwald
Employment - Flatiron Health
Stock and Other Ownership Interests - Roche
 
Philani Mpofu
Employment - Flatiron Health
Stock and Other Ownership Interests - Roche
 
Ivy Altomare
Employment - Flatiron Health
Stock and Other Ownership Interests - Roche
 
Arun Sujenthiran
Employment - Flatiron Health
Stock and Other Ownership Interests - Roche
 
Trevor Joseph Royce
Employment - ArteraAI; Flatiron Health
Stock and Other Ownership Interests - Lumata Health; mPATH; Roche; SonoVascular; VitriVax
Consulting or Advisory Role - Agilix Health
 
Christoph Buhl
Employment - Flatiron Health
Stock and Other Ownership Interests - Roche
 
Viktor Grünwald
Employment - University Hospital Essen
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Genmab; MSD; Seagen
Honoraria - Advanced Accelerator Applications/Novartis; Amgen; Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Nanobiotix; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Cor2Ed; Cureteq; Debiopharm Group; Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Oncorena; Onkowissen; PCI Biotech; Pfizer; Synthekine
Research Funding - Amgen (Inst); BMS (Inst); Gilead Sciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Serono; Pfizer
 
Ken Herrmann
Leadership - Pharma15; SOFIE; Theragnostics
Stock and Other Ownership Interests - AdvanCell; Aktis Oncology; Convergent Therapeutics; Pharma15; SOFIE; Theragnostics
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; AstraZeneca; Bain Capital; Bayer; Boston Scientific; BTG; Debiopharm Group; Fusion Pharmaceuticals; GE Healthcare; Immedica; IPSEN; ITG (Inst); Janssen Oncology; Molecular Partners; Novartis; Radiopharm Theranostics; ROTOP Pharmaka (Inst); Siemens Healthineers; Telix Pharmaceuticals
 
Jens Kleesiek
No Relationships to Disclose
 
Boris A. Hadaschik
Consulting or Advisory Role - ABX Advanced biochemical compounds; Accord Healthcare; Amgen; Astellas Pharma; Bayer; BMS GmbH & Co. KG; Ipsen; Janssen; Lightpoint medical; Merck KGaA; MSD; Novartis; Onkowissen; Pfizer; POINT Biopharma
Research Funding - Bristol Myers Squibb (Inst); Janssen; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Uromed
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; Ipsen; Janssen